SELLAS Life Sciences (SLS) Net Equity Issued and Repurchased (2011 - 2023)
SELLAS Life Sciences (SLS) posted quarterly Net Equity Issued and Repurchased of $21000.0 for Q4 2023, down 97.74% year-over-year from $929000.0 in Q4 2022, and down 92.16% quarter-over-quarter from $268000.0 in Q1 2023.
SELLAS Life Sciences (SLS) Net Equity Issued and Repurchased (2011 - 2023) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Net Equity Issued and Repurchased for 13 consecutive years, with $21000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Net Equity Issued and Repurchased fell 97.74% year-over-year to $21000.0; the TTM figure through Sep 2024 stood at $21000.0 (down 98.25% YoY), while the FY2023 annual figure was $289000.0, down 72.42% from the prior year.
- Net Equity Issued and Repurchased fell to $21000.0 in Q4 2023 per SLS's latest filing, from $268000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $15.1 million in Q4 2020 and bottomed at -$129000.0 in Q3 2019.
- Historically, Net Equity Issued and Repurchased has averaged $3.8 million across 5 years, with a median of $929000.0 in 2022.
- Annual changes were most pronounced in 2019 — Net Equity Issued and Repurchased tumbled 100.6% — and 2020, when it jumped 6682.95%.
- SELLAS Life Sciences' Net Equity Issued and Repurchased stood at $2.3 million in 2019, then surged by 553.04% to $15.1 million in 2020, then plunged by 85.21% to $2.2 million in 2021, then sank by 58.53% to $929000.0 in 2022, then slumped by 97.74% to $21000.0 in 2023.
- Business Quant data shows SLS's Net Equity Issued and Repurchased at $21000.0 in Q4 2023, $268000.0 in Q1 2023, and $929000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 21,000.00 |
| Dec 31, 2023 | 21,000.00 |
| Mar 31, 2023 | 268,000.00 |
| Mar 31, 2023 | 268,000.00 |
| Dec 31, 2022 | 929,000.00 |
| Dec 31, 2022 | 929,000.00 |
| Sep 30, 2022 | 69,000.00 |
| Sep 30, 2022 | 69,000.00 |
| Jun 30, 2022 | 50,000.00 |
| Jun 30, 2022 | 50,000.00 |
| Sep 30, 2021 | 2.24 Mn |
| Sep 30, 2021 | 2.24 Mn |
| Dec 31, 2020 | 15.14 Mn |
| Dec 31, 2020 | 15.14 Mn |
| Sep 30, 2020 | 8.49 Mn |
| Sep 30, 2020 | 8.49 Mn |
| Jun 30, 2020 | -25,000.00 |
| Jun 30, 2020 | -25,000.00 |
| Mar 31, 2020 | 5.99 Mn |
| Mar 31, 2020 | 5.99 Mn |